Eli Lilly (LLY) earnings Q1 2026

Key Points:

• Eli Lilly reported first-quarter earnings and revenue that exceeded expectations, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro, prompting a $2 billion increase in its full-year sales outlook to $82-$85 billion for 2026.
• The company's adjusted profit forecast was raised to $35.50-$37 per share, up from $33.50-$35, reflecting robust sales despite lower realized prices in the U.S. market.
• Mounjaro's worldwide revenue surged 125% to $8.66 billion, surpassing analyst estimates, while Zepbound's U.S. revenue rose 80% to $4.16 billion, maintaining Lilly's dominant 60.1% share of the U.S. GLP-1 obesity and diabetes drug market.
• Lilly posted net income of $7.40 billion ($8.26 per share) for the quarter, significantly higher than the previous year's $2.76 billion, with U.S. revenue growth driven by a 49% increase in prescription volume.
• The newly approved GLP-1 obesity pill Foundayo launched in Q2, with early sales described as "modest," and is expected to be a key topic in upcoming earnings discussions amid competition from Novo Nordisk's Wegovy and ongoing pricing pressures.